Abstract Survivin is a tumor-associated antigen (TAA) that has signiWcant potential for use as a cancer vaccine target. To identify survivin epitopes that might serve as targets for CTL-mediated, anti-tumor responses, we evaluated a series of survivin peptides with predicted binding to mouse H2-K b and human HLA-A*0201 antigens in peptide-loaded dendritic cell (DC) vaccines. H2-K b -positive, C57BL/6 mice were vaccinated using syngeneic, peptide-loaded DC2.4 cells. Splenocytes from vaccinated mice were screened by Xow cytometry for binding of dimeric H2-K b :Ig to peptide-speciWc CD8+ T cells. Two survivin peptides (SVN 57-64 and SVN 82-89 ) generated speciWc CD8+ T cells. We chose to focus on the SVN 57-64 peptide because that region of the molecule is 100% homologous to human survivin. A larger peptide (SVN 53-67 ), containing multiple class I epitopes, and a potential class II ligand, was able to elicit both CD8+ CTL and CD4+ T cell help. We tested the SVN 53-67 15-mer peptide in a therapeutic model using a peptide-loaded DC vaccine in C57BL/6 mice with survivinexpressing GL261 cerebral gliomas. This vaccine produced signiWcant CTL responses and helper T cell-associated cytokine production, resulting in a signiWcant prolongation of survival. The SVN 53-67 vaccine was signiWcantly more eVective than the SVN 57-64 core epitope as a cancer vaccine, emphasizing the potential beneWt of incorporating multiple class I epitopes and associated cytokine support within a single peptide.
Introduction
Even with intensive treatment, malignant gliomas frequently recur as a result of continued growth of residual microscopic disease located beyond surgical resection margins [1, 2] . Surgery, radiation therapy and chemotherapy provide deWnite therapeutic beneWt, but long-term survival is uncommon [3] . This situation has stimulated interest in exploring the usefulness of immunotherapy for patients with malignant gliomas.
Survivin is one of the most speciWc cancer antigens identiWed to date because it is expressed in a large percentage of tumors and is rarely detectable in normal tissue [4, 5] . Survivin expression occurs commonly in malignant gliomas [6] [7] [8] where its expression is associated with a poor prognosis [7, 9] . Also, because survivin is expressed by many diVerent cancer types, its use as a tumor vaccine target may have broad implications for cancer vaccine therapy.
Epitopes of intracellular proteins, including those of survivin, appear on the surface of tumor cells in association with MHC I molecules. CD8+ CTLs are activated by tumor-derived peptides coupled to MHC class I antigens. The tumor antigen-MHC class I peptide complex binds to the antigen-speciWc T cell receptor on CD8+ cells and stimulates T cell activation. Thus, certain survivin epitopes that are correctly presented by tumor cells and are recognized by speciWc T cells may elicit potent antitumor responses [10] . Therefore, identiWcation of survivin peptides that can bind to MHC class I molecules and elicit strong cellular immune responses is an important goal of anti-survivin cancer immunotherapy.
The generation of an eVective and speciWc cell-mediated immune response may require the activation of both highly speciWc CD8+ lymphocyte subsets and CD4+ helper T cells. To activate a CD4+ T cell response, antigens must be presented to CD4+ T cells in conjunction with an MHC class II antigen. Once CD4+ cells have been activated, they proliferate and produce cytokines (e.g. IFN-, IL-2, and IL-4) that enhance the immune response. These cytokines are essential to provide a fully activated CD8+ antitumor CTL response.
The current study is based on our preliminary observation that a DNA vaccine against survivin inhibits the growth of malignant glioma in rats and mice [11, 12] . We previously demonstrated that a CTL response could be generated using the entire survivin molecule, as well as with speciWc domains of survivin, and that the responses generated from these could have a beneWcial eVect against cerebral gliomas [12] . In our current study, we set out to design a survivin peptide based upon a study of the immunogenicity of smaller peptides with predicted binding to both human and mouse MHC class I molecules. The purpose of this approach was to develop a survivin peptide that would be suitable for clinical application.
Here we hypothesized that a single peptide with multiple epitopes could be capable of eliciting an eVective immune response to survivin epitopes presented on tumor cells. We also speculated that incorporation of CD4+ helper cell support of that immune response would promote a more robust antitumor response. We studied a peptide vaccine strategy based upon survivin amino acid sequences that are capable of stimulating CD8+ speciWc T cells against several diVerent epitopes of survivin. In addition, we investigated a strategy using a larger survivin peptide containing a potential MHC class II ligand that is present in the survivin molecule to stimulate CD4+ cytokine-secreting helper T cells.
Materials and methods
Cell lines and culture conditions GL261 murine glioma cells were grown on 100-mm tissue culture plates in complete Dulbecco's modiWed Eagle's medium (DMEM) containing 10% fetal calf serum, 5,000 units penicillin/streptomycin, 50 M 2-mercaptoethanol, 25 mM HEPES, and 1£ non-essential amino acids at 37°C in 5% CO 2 with media changes two to three times per week. The DC2.4 dendritic cell line was provided by Dr. Ken Rock (University of Massachusetts Medical School), and RMA-S cells were provided by Dr. Ron Germain (NIH).
Peptides
Peptide synthesis was performed using Fmoc chemistry and a solid support resin (Sigma-Genosys, The Woodlands, TX). Each peptide was stored at ¡20°C until use and initially diluted in DMSO. The following peptide sequences were synthesized SVN [9] [10] [11] [12] [13] [14] [15] [16] 
Peptide binding
Computer predictions of peptide binding were determined utilizing the "SYFPEITHI" program [13] . The prediction is based on published motifs (pool sequencing, natural ligands) and takes into consideration the amino acids in the anchor and auxiliary anchor positions, as well as other frequent amino acids. Peptides were chosen for studies based upon strong binding predictions to both H2-K b and HLA-A*0201. Direct binding of survivin peptides to H2-K b molecules was quantitated by Xow cytometry analysis of RMA-S cells [14] . RMA-S cells (deWcient for expression of peptide loaded surface MHC class I) were cultured at 27°C for 24 h, after which 6 £ 10 5 per 50 l of PBS supplemented with 20% FCS were incubated with 50 l of PBS containing 100 M peptide 27°C for 1 h and transferred to 37°C for 3 h. After washing with PBS, cells were incubated with anti-H2-K b mAb (AF6-88.5) (Biolegend) followed by goat anti-mouse PE conjugated (FabЈ) 2 (DAKO). The upregulation of H2-K b molecules after binding with speciWc peptides was shown as mean Xuorescence representative of increased binding characteristics of SVN peptides. OVA 258-265 peptide was used as a positive control for H2-K b binding. A random peptide (RND) without any known anchor motifs was used as a negative binding control.
Immunization of mice with peptide-loaded DCs DC2.4 cells were maintained via in vitro cell culture. Prior to vaccination 1 £ 10 7 cells were pulsed with 100 g of peptide at 37°C for 2 h. Cells were washed and re-suspended in PBS. Four days after tumor implantation, 1 £ 10 6 peptide-loaded DCs were injected subcutaneously into C57BL/6 mice. This inoculation was repeated as a booster vaccination 7 and 14 days later.
Splenocyte and T cell isolation C57BL/6 mice were vaccinated with survivin peptideloaded DC2.4 cells at weekly intervals for a total of three immunizations. Splenic tissue of vaccinated mice was harvested at endpoint sacriWce. Cells were teased from mouse spleens with sterile forceps and passed through a 70 m Wlter (BD Falcon). Splenocytes were cultured in DMEM containing 10% fetal bovine serum, IL-2 (10 units/ml) and IL-7 (1 ng/ml). Medium was replenished on day 2. To isolate T cells, splenocytes were centrifuged for 5 min and the pellet was re-suspended in RBC lysis buVer (R&D Systems). Cells were washed twice and re-suspended in complete RPMI culture medium. Re-stimulation of splenocytes from immunized mice was performed in vitro for 5 days in media containing 10 g/ml peptide. Ig complexes were prepared as a staining cocktail with antimouse PE conjugated (FabЈ) 2 (DAKO). Splenocytes were resuspended in FACS staining buVer (PBS, 1% FCS, 0.1% sodium azide) at 1 £ 10 6 cells and treated with 20 g rat anti-mouse CD16/CD32 FcgIII/II receptor block (BD Biosciences Pharmingen). Cells were doubly stained for CD8 using a FITC-conjugated rat anti-mouse CD8 mAb (GK1.2) (Biolegend). Flow cytometry with dimers was performed with 3 £ 10 5 cells per sample. Cells were washed in FACS wash buVer containing 0.2% FBS and 0.5% sodium azide. Cells were incubated in antibodies and complexes for 1 h at 4°C, washed and prepared for FACS analysis. Final data were analyzed using FCS Express software. Analysis is based upon gating on CD8+ T cells only.
Tumor cell lysis by CTL Cellular assays for speciWc T cell lysis of target were performed using the Live/Dead cell-mediated cytoxicity kit (Molecular Probes-Invitrogen). GL261 cells were trypsinized and suspended at 1 £ 10 6 cells/ml followed by addition of 10 l DiOC 18 label (green Xuorescence) for 20 min at 37°C. After labeling, cells were centrifuged, washed in PBS twice, and resuspended at 1 £ 10 6 cells/ml of DMEM. Next, 1 £ 10 4 GL261 DiOC 18 -labeled target cells were added to individual culture tubes. Splenocytes from vaccinated animals were added to the target cells in ratios ranging from 1:5 to 1:100 for 2 h at 37°C. Conditions were also set up to assay background levels, spontaneous membrane integrity loss and maximal lysis. Propidium Iodide was added to each tube to label cells with permeated cell membranes red. Cells were pelleted and used for FACS analysis. Percentage cytotoxicity was calculated using the formula: (experimental PI-DiOC 18 cells ¡ spontaneous)/(maximum PI-DiOC 18 ¡ spontaneous PI-DiOC 18 ) £ 100. Maximum release was determined by ethanol treatment of DiOC 18 labeled target cells. Spontaneous release was measured by incubating PI-DiOC 18 cells in the absence of eVector cells. Final data were analyzed using FCS Express software. Analysis is based upon gating on GL261 cells to eliminate any background from eVector cells.
Intracellular cytokine staining
Splenocytes from immunized mice were stimulated in vitro via survivin peptides. Cells were harvested and surface stained with anti-mouse CD4 PE/Cy5 (GK1.5) (Biolegend) for CD4 surface antigen, then Wxed with paraformaldehyde to stabilize the cell membrane and permeabilized with saponin. Anti-mouse IL-2 FITC (JES6-5H4), anti-mouse IFN FITC (XMG1.2), anti-mouse IL-4 PE (11B11) (eBiosciences) were used to stain for intracellular cytokines at pre-titrated concentrations. Commercially prepared mouse in vitro activated splenocytes known to contain IL-2, IL-3, IL-4, IL-10, GM-CSF, IFN-expressing cells (eBiosciences) were used as positive control cells. BrieXy, cells were incubate in the dark at room temperature for 20 min with mAb combinations, washed in permeabilization buVer, resuspended in staining buVer without saponin and prepared for FACS analysis. Final data was analyzed using FCS Express software. Analysis is based upon gating on CD4+ T cells only.
Intracerebral GL261 tumor cell injection and survival analysis
Male C57BL/6 mice were anesthetized with an intraperitoneal (i.p.) injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) and Wxed in a stereotactic head frame (David Kopf Instruments, Tujunga, CA). A midline scalp incision was made and the bregma was identiWed. Stereotactic coordinates were measured (2.0 mm lateral, and 1.2 mm anterior to the bregma) for implantation of cells into the deep frontal white matter. A burr hole was drilled at this point and 1 £ 10 5 GL261 cells suspended in 2.5 l of DMEM were injected through a Hamilton syringe with a Wxed, 25-gauge needle at a depth of 3.0 mm relative to the dura mater. Injections were performed at 1 l/min. The needle was withdrawn and the incision sutured. Kaplan-Meier survival plots were drawn and median survival times were determined for all groups. Survival diVerences were assessed for signiWcance using the logrank Mantel-Cox method.
Results

H2-K
b binding of survivin epitopes Table 1 shows predicted binding for each of the survivin peptides using SYFPEITHI analysis. Upregulation of H2-K b molecules on the surface of murine RMA-S cells (deWcient for expression of peptide loaded surface MHC class I) was used to determine actual peptide binding in vitro. Mean Xuorescence represent increased binding characteristics of SVN peptides. Data shows the binding of 100 M peptide at 37°C. The negative control peptide (random) does not contain anchor binding residues. The positive control (OVA 258-265 ) peptide is a known immunogenic MHC class I ligand. As predicted by SYFPEITHI analysis and conWrmed in actual cell binding assays ( Fig. 1) , SVN 57-64 and SVN 82-89 displayed the highest aYnity for MHC-I. We continued to focus upon SVN 57-64 based peptides, as this region of the survivin molecule is 100% homologous to human survivin.
CTL responses against GL261 cells
We tested splenocytes from mice immunized and boosted with peptide-loaded DC2.4 cells for their ability to kill survivin expressing GL261 glioma cells in culture (Fig. 2) . CTL assays revealed signiWcant cytotoxic eVects from eVector lymphocytes of SVN 57-64 and SVN 82-89 vaccinated mice against GL261 target cells, but not from lymphocytes of OVA 258-265 peptide loaded DC vaccinated mice (not shown), consistent with the presence of speciWc anti-survivin CTL response. Although SVN 82-89 produced a higher cytotoxic eVect, we have chosen to focus on SVN 57-64 based peptides, as this region of the survivin molecule is 100% homologous to human survivin and can avoid xenogeneic responses.
SpeciWc CD8+ T cells against naturally processed survivin epitopes
We analyzed splenocytes from mice immunized and boosted with full length survivin cDNA transfected DC2.4 cells for the presence of CD8+ T cells capable of recognizing the indicated peptide epitopes after re-stimulation in vitro (Fig. 3) . FACS analysis utilizing speciWc peptide-loaded H2-K b dimer IgG and gated on the CD8+ T cell population detected CD8+ T cells that were speciWc for SVN 57 peptide epitopes (Fig. 4) Using SVN 57-64 as the basis (core) for the design of a larger peptide capable of stimulating CD4+ T cell support, we designed a peptide with additional amino acids Xanking SVN 57-64 . As a result, this produced a larger peptide that is predicted to bind human, and possibly murine, class II molecules, while retaining numerous internal MHC class I ligands in addition to those present in the core SVN 57-64 peptide ( Table 2 ). Of note, the 15-amino acid sequence of SVN [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] contained in this peptide is also 100% homologous between mouse and human survivin proteins. Thus, SVN 53-67 may be applicable as a peptide vaccine in both mouse and humans. (Fig. 6) . The SVN 53-67 (15-mer) strongly stimulated IL-4 and IFN production, but not IL-2 production. In contrast, the smaller survivin peptides, including SVN 56-64 , which contained the core SVN 57-64 motif, failed to stimulate either IL-4 or IFN . These results indicated that the larger 15-mer peptide (SVN 53-67 ) was indeed capable of stimulating CD4+ T cell based cytokine support while smaller peptides (SVN 56-64 SVN 57-64 ) did not.
Survival of C57BL6 mice with intracerebral GL261 glioma implants treated with survivin peptide DC vaccines C57BL/6 mice were immunized with SVN 53-67 , SVN 57-64 , SVN 82-89 , or OVA 258-265 peptide loaded DC2.4 cells. Vaccinations began 4 days after tumor cell implantation and were repeated (boosted) every 7 days to simulate a therapeutic setting (Fig. 7) . While the smaller survivin peptides, SVN 57-64 and SVN 82-89 produced strong CTL responses and speciWc CD8+ T cells in vitro, these peptides were not highly eVective in vivo against murine survivin expressing GL261 cerebral gliomas (Table 3 ). In contrast, the SVN 53-67 (15-mer) which contains multiple internal MHC class I ligands and at least one MHC class II ligand, was signiWcantly more eVective (>200% increase in survival) than any other smaller peptides in vivo. This result appears to be associated with the ability of the SVN 53-67 15-mer peptide to initiate both CD4+ and CD8+ T cell responses. 
Discussion
Survivin is an important tumor-associated antigen with restricted expression [4, 15, 16] . This characteristic makes it an excellent candidate target antigen for antitumor vaccines. MHC class I-restricted cytotoxic T cells directed against survivin peptides have been identiWed in patients with breast cancer, leukemia and melanoma [17] . Peptide epitopes from tumor-associated antigens (TAA), including survivin, can be recognized by cytotoxic T lymphocytes (CTL) in the context of MHC I molecules [10] . The human survivin protein contains HLA-A*0201 (HLA-A2) binding motifs. Andersen et al. [18] used HLA-A2-restricted peptides to test for speciWc T-cell reactivity in leukemia and melanoma patients. CTL responses against two survivin epitopes were detected in both patient groups, but no T cell reactivity was found in healthy control patients. Therefore, self-immunization with the survivin molecule appears to take place in some tumor patients. This raises the possibility that immunization with survivin epitopes could stimulate a memory response with therapeutic beneWt for cancer patients. Schmitz et al. [19] were the Wrst to show that two survivin peptides (ELTLGEFLKL and TLPPAWQPFL) can bind to HLA-A*0201 and elicit CD8+ immune responses when presented by DC. Moreover, one of these peptides was shown to result from the natural intracellular processing of survivin. These studies demonstrated that survivin is recognizable by autologous T cells. In addition, the identiWcation of HLA-A1, HLA-A2, HLA-A3, and HLA-A11-restricted survivin epitopes [10] suggests that it might be possible to target survivin-expressing tumor cells using survivin-based cancer vaccines for a large clinical population.
In the current study, we have shown that the survivin protein is processed into additional peptides that elicit a class I immune response capable of being re-stimulated by SVN 57-64 and SVN 82-89 peptides (Figs. 3, 4 ). This is a further indicator of the natural processing of survivin into potentially immunogenic epitopes, not previously described. The fact that immune response to SVN [18] [19] [20] [21] [22] [23] [24] [25] , SVN 39-46 , SVN [9] [10] [11] [12] [13] [14] [15] [16] , SVN 97-104 peptides were not detected in these animals could be attributed to one or more of the following: (1) suboptimal class I binding by these peptides, (2) lack of adequate T cell receptor interaction with the peptides in the context of class I, and (3) lack of appropriate processing of the survivin protein.
Peptides processed from SVN 53-67 are capable of binding HLA-A*0201 and are predicted to bind many additional common HLA molecules, including: A*03, A*1101, A*2402, A*26, A*6801, B*0702, B*08, B*1402, B*1501(B62), B*1510, B*18, B*2705, B*2709, B*3901, B*4402 and B*5101. Therefore, just as SVN 53-67 is immunogenic in mice, it should be immunogenic in humans expressing the appropriate MHC-I haplotypes.
Immunotherapy has emerged as a potential treatment modality for cerebral gliomas because it is: (1) speciWc to tumor cells, (2) has the potential to eradicate inWltrating tumor cells after surgical debulking, and (3) may be capable of eliciting a long-lasting memory response to prevent tumor recurrence. Both immunological [20] [21] [22] and clinical responses [22, 23] have been observed in glioma patients immunized with (1) dendritic cells (DC) loaded with peptides eluted from the surface of allogeneic tumor cells [20] ; (2) DC loaded with peptides eluted from autologous tumor cells [21] ; (3) DC pulsed with tumor lysate from autologous tumor cells [22] ; and (4) hybrids generated by fusing DC with autologous tumor cells [23] . In one study [22] , patients with recurrent glioblastoma multiforme, who were immunized with tumor lysate-pulsed DCs, had increased survival (median = 133 weeks). Thus, DCs oVer signiWcant potential as an immunization vehicle to treat malignant gliomas.
More speciWcally, Zeis et al. [24] have shown that transfection of dendritic cells (DC) with survivin mRNA leads to resistance to tumor challenge. Xiang et al. [25] showed that a DNA-based survivin vaccine could produce a CTL response against Lewis lung carcinoma with regression of both primary tumor and pulmonary metastases. The mechanism of the antitumor immunity induced by this DNA vaccine involved MHC class I antigen-restricted CD8+ T cells. The survivin vaccine triggered tumor cell apoptosis, together with release of IFN . Similarly, others have shown that survivin DNA vaccines generate speciWc antitumor eVects with increased lymphocyte inWltration at tumor sites [26, 27] . Recently a SVN 85-93 peptide combined with a plasmid encoding murine interleukin-15 (IL-15) was shown to support robust, CTL-mediated, long-term, immunity in vivo when used as a tumor vaccine. This vaccine eVectively protected BALB/c mice against fatal CT26 tumor challenge [28] .
Another distinct survivin derived peptide epitope "SVN 10 " was used to derive T cell clones from cancer patients with multiple HLA-DR genotypes capable of recognizing naturally processed antigen [29] . In addition, an anti-DEC205-human survivin protein was able to stimulate CD4+ T cell responses better than approaches involving survivin plasmid DNA or survivin peptides with adjuvants, but was unable to induce CD8+ T cell immunity [30] . Each of these reports conWrms the ability of survivin vaccines to generate CTL responses and the importance of cytokine support. Our study describes the Wrst deWned survivin peptide vaccine that is capable of stimulating a response to multiple CD8+ T cell epitopes and a CD4+ T cell cytokine response from a deWned, single-peptide immunogen.
The eVectiveness of a peptide vaccine may be enhanced by the capacity of DC to present both class I and class II associated epitopes. SVN 53-67 is processed to expose diVerent epitopes for CD8+ T cell recognition and is capable of stimulating CD4+ T helper cells as well. Thus, SVN 53-67 represents a potential class II ligand in C57BL/6 mice. In our study, the smaller core peptides (SVN 57-64 and SVN 56-64 ) stimulated CD8+ responses and produced eVective CTL in vitro. However, these same core peptides only produced modest prolongation of survival of mice with cerebral gliomas. In contrast, the SVN 53-67 15-mer produced signiWcant prolongation of survival in this model. Thus, the addition of CD4+ support may contribute to a more eVective antitumor response in vivo.
Our study shows that the contribution of CD4 support may lead to a more eVective peptide vaccine strategy. The enhanced survival demonstrated by SVN [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] suggests that the addition of CD4+ helper T cell support associated with a speciWc survivin-derived CD8+ T cell response may lead to a more eVective peptide antitumor vaccine. Other studies of ours indicate that SVN 53-67 is capable of re-stimulating an autologous human CTL response capable of lysing tumor cells ex vivo (data not shown). In addition, SVN 53-67 is predicted to function as a ligand for HLA-DRB1*0301 (DR17), HLA-DRB1*0401 (DR4Dw4), HLA-DRB1*0701, HLA-DRB1*1501 (DR2b) molecules, making it potentially capable of stimulating CD4 + support in humans. A peptide vaccination strategy combining CTL and CD4+ support provides one additional avenue to investigate for survivintargeted, immunotherapeutic approaches for cerebral gliomas.
